CTX-M-190, a Novel β-Lactamase Resistant to Tazobactam and Sulbactam, Identified in an Escherichia coli Clinical Isolate.
A novel β-lactamase, CTX-M-190, derived from CTX-M-55 by a single substitution of Ser for Thr at position 133 (Ser133Thr), was identified in a natural Escherichia coli clinical isolate. CTX-M-190 exhibited potent hydrolytic activity against cefotaxime, with a kcat/Kmratio of 14.5 μM-1s-1, and was highly resistant to inhibition by the β-lactamase inhibitors tazobactam and sulbactam, whose 50% inhibitory concentrations were 77- and 55-fold higher, respectively, for CTX-M-190 than for CTX-M-55. blaCTX-M-190was located within the genetic platform ISEcp1-blaCTX-M-orf477, which was harbored by a 70-kb IncI1 plasmid.
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Zhen
Z
Shen
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Baixing
B
Ding
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Yingmin
Y
Bi
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Shi
S
Wu
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Su
S
Xu
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Xiaogang
X
Xu
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Qinglan
0000-0003-2490-1201
Q
Guo
Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China mgwang@fudan.edu.cn.|Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Minggui
M
Wang
D019943:Amino Acid Substitution; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology; D002439:Cefotaxime / Q000378:metabolism* / Q000494:pharmacology; D003001:Cloning, Molecular; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology / Q000235:genetics* / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D015870:Gene Expression; D006801:Humans; D020128:Inhibitory Concentration 50; D008875:Middle Aged; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010957:Plasmids / Q000737:chemistry / Q000378:metabolism*; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D018440:beta-Lactam Resistance / Q000235:genetics*; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D001618:beta-Lactamases; D002439:Cefotaxime; D013407:Sulbactam; D000078142:Tazobactam
CTX-M-190; Escherichia coli; inhibitor-resistant β-lactamase; sulbactam; tazobactam